A client with chronic kidney disease has a prescription for epoetin alfa. How should this medication be administered?

Epoetin alfa is typically administered subcutaneously to patients, especially those with chronic kidney disease who require erythropoiesis-stimulating agents due to anemia. This route allows for gradual absorption and is often more comfortable for patients, enabling them to potentially administer the injection themselves at home.

While intravenous administration is an option often utilized in certain hospital settings, such as during dialysis, subcutaneous administration is generally preferred for ongoing management outside of acute care, particularly for outpatient settings. Oral and intradermal routes are not appropriate for this medication, as they would not provide the necessary systemic effect on erythropoiesis. Thus, subcutaneous administration aligns with the standard practice for managing anemia in those with chronic kidney disease through the use of epoetin alfa.